An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015
M Vichnin, P Bonanni, NP Klein… - The Pediatric …, 2015 - journals.lww.com
Background: A quadrivalent human papillomavirus (HPV4) type 6/11/16/18 vaccine
(GARDASIL/SILGARD®) has been licensed in many countries around the world for the …
(GARDASIL/SILGARD®) has been licensed in many countries around the world for the …
The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil
RM Haupt, HL Sings - Journal of Adolescent Health, 2011 - Elsevier
Human papillomavirus (HPV) infection causes cervical cancer, a significant portion of anal,
genital, and oropharyngeal cancers, genital warts, and recurrent respiratory papillomatosis …
genital, and oropharyngeal cancers, genital warts, and recurrent respiratory papillomatosis …
Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil®)
MAA Siddiqui, CM Perry - Drugs, 2006 - Springer
Abstract▴ Human papillomavirus (HPV) quadrivalent recombinant vaccine is a mixture of
virus-like particles derived from the L1 capsid proteins of HPV types 6, 11, 16 and 18. It is …
virus-like particles derived from the L1 capsid proteins of HPV types 6, 11, 16 and 18. It is …
A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil …
T Vesikari, N Brodszki, P van Damme… - The Pediatric …, 2015 - journals.lww.com
Background: A 9-valent human papillomavirus (9vHPV) vaccine has been developed to
prevent infections and diseases related to HPV 6/11/16/18 [as per the licensed quadrivalent …
prevent infections and diseases related to HPV 6/11/16/18 [as per the licensed quadrivalent …
An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given …
T Vesikari, P Van Damme, N Lindblad… - The Pediatric …, 2010 - journals.lww.com
Background: GARDASIL/SILGARD is a quadrivalent human papillomavirus (HPV) vaccine
with activity against HPV 6/11/16/18. In many countries, GARDASIL is recommended for …
with activity against HPV 6/11/16/18. In many countries, GARDASIL is recommended for …
[HTML][HTML] Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women
ÁM Ruiz-Sternberg, ED Moreira Jr, JA Restrepo… - Papillomavirus …, 2018 - Elsevier
Background A 9-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58; 9vHPV)
vaccine was developed to expand coverage of the previously developed quadrivalent …
vaccine was developed to expand coverage of the previously developed quadrivalent …
[HTML][HTML] Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after …
SE Olsson, JA Restrepo, JC Reina, P Pitisuttithum… - Papillomavirus …, 2020 - Elsevier
Background The nine-valent human papillomavirus (9vHPV) vaccine protects against
infection and disease related to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The pivotal …
infection and disease related to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The pivotal …
Long-term study of a quadrivalent human papillomavirus vaccine
D Ferris, R Samakoses, SL Block… - …, 2014 - publications.aap.org
BACKGROUND: We present a long-term safety, immunogenicity, and effectiveness study of
a quadrivalent human papillomavirus (HPV4) vaccine. METHODS: Sexually naive boys and …
a quadrivalent human papillomavirus (HPV4) vaccine. METHODS: Sexually naive boys and …
Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials
ED Moreira, SL Block, D Ferris, AR Giuliano… - …, 2016 - publications.aap.org
OBJECTIVES: The overall safety profile of the 9-valent human papillomavirus (9vHPV)
vaccine was evaluated across 7 Phase III studies, conducted in males and females …
vaccine was evaluated across 7 Phase III studies, conducted in males and females …
HPV vaccine recommendations
Committee on Infectious Diseases - Pediatrics, 2012 - pubmed.ncbi.nlm.nih.gov
On October 25, 2011, the Advisory Committee on Immunization Practices of the Centers for
Disease Control and Prevention recommended that the quadrivalent human papillomavirus …
Disease Control and Prevention recommended that the quadrivalent human papillomavirus …